Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOKIO: Third-line TKI in mRCC
NCT03456401Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib and sunitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Median Progression Free Survival up to 5 years. Started Nov 2014; status: terminated.
02
Drugs
sorafenibsunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03456401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456401.